ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White B... (those caused by influenza virus) autoimm...)

ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells

Date:8/27/2007

those caused by influenza virus), autoimmune disorders, certain medications (including most cytotoxic chemotherapy), radiation and bone marrow diseases such as leukemia or myelodysplastic syndromes. Replenishment of leukocytes at early time periods following irradiation could result from proliferation and maturation of a pluripotential stem cell subset that is protected from the damaging effect of radiation. Further studies are in process to delineate the mechanism of leukocyte replenishment.

About TGen

The Translational Genomics Research Institute (TGen), a non-profit 501(c)(3) organization, is focused on developing earlier diagnostics and smarter treatments. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases. TGen's research is based on personalized medicine and the institute plans to accomplish its goals through robust and disease-focused research.

About Radilex(TM) and Viprovex(R)

Radilex(TM) is the trade name used in referring to formulations of Homspera(TM) for potential indications for treatment of exposure to ionizing radiation. Viprovex(R) is the trade name used in referring to formulations of Homspera(TM) for potential indications for treatment of viral and bacterial infections. Homspera(TM) is a generic name used by the Company to describe the synthetic peptide Sar9, Met (O2)11-Substance P. Sar9, Met (O2)11-Substance P is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species. All of the Company's research and development efforts are early, pre-clinical stage and Homspera(TM), as Viprovex(R) and Radilex(TM), has only undergone exploratory studies to evaluate its biological activity in small animals.<
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
2. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression

Post Your Comments:

ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White B...(those caused by influenza virus) autoimm...),Health